Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial-Reference-Cited by-同舟云学术

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Published:2019-05-08 Issue:17 Volume:125 Page:2965-2974
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pinsky Paul F.¹^ORCID,Black Amanda²,Daugherty Sarah E.³,Hoover Robert²,Parnes Howard¹,Smith Zachary L.⁴,Eggener Scott⁵,Andriole Gerald L.⁴,Berndt Sonja I.²

Affiliation:

1. Division of Cancer Prevention National Cancer Institute, National Institutes of Health Bethesda Maryland

2. Division of Cancer Epidemiology and Genetics National Cancer Institute, National Institutes of Health Bethesda Maryland

3. Patient‐Centered Outcomes Research Institute Washington DC

4. Washington University School of Medicine St. Louis Missouri

5. University of Chicago School of Medicine Chicago Illinois

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32176

Reference16 articles.

1. Screening for Prostate Cancer

2. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

3. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality

4. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

5. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers;Non-coding RNA Research;2024-12

2. Predictive value of controlling nutritional status score for prostate cancer diagnosis;Frontiers in Oncology;2024-02-21

3. The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality;European Urology Oncology;2023-12

4. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer;Future Oncology;2023-10-26

5. Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990–2019: A Systematic Analysis from the Global Burden of Disease Study;Journal of Epidemiology and Global Health;2023-05-06